Format

Send to

Choose Destination
Trends Cogn Sci. 2013 Oct;17(10):510-6. doi: 10.1016/j.tics.2013.08.007. Epub 2013 Sep 9.

Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings.

Author information

1
Imaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095, USA. Electronic address: braskie@usc.edu.

Abstract

Brain amyloid can be measured using positron emission tomography (PET). There are mixed reports regarding whether amyloid measures are correlated with measures of cognition (in particular memory), depending on the cohorts and cognitive domains assessed. In Alzheimer's disease (AD) patients and those at heightened risk for AD, cognitive performance may be related to the level and extent of classical AD pathology (amyloid plaques and neurofibrillary angles), but it is also influenced by neurodegeneration, neurocognitive reserve, and vascular health. We discuss what recent neuroimaging research has discovered about cognitive deficits in AD and offer suggestions for future research.

KEYWORDS:

MRI; PET; dementia; executive function; memory; mild cognitive impairment

PMID:
24029445
PMCID:
PMC3947610
DOI:
10.1016/j.tics.2013.08.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center